NVCT
HEALTHCARENuvectis Pharma Inc
AI Insight
What's Moving NVCT Today?
No stock-specific AI insight has been generated for NVCT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.55$18.24
$17.55
Fundamentals
Market Cap$471M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-154.4%
Profit Margin—
Debt / Equity—
Trading
Volume281K
Avg Volume (10D)—
Shares Outstanding26.5M
NVCT News
22 articles- Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement IndicationsYahoo Finance·Jun 23, 2026
- Nuvectis (NASDAQ: NVCT) inks Haisco deal for NXP100 and BRAF drug NXP200Stock Titan·Jun 23, 2026
- Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)Advfn·Jun 22, 2026
- Nuvectis licenses two clinical-stage drugs from Haisco By Investing.comInvesting.com Canada·Jun 22, 2026
- Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage CompoundsYahoo Finance·Jun 22, 2026
- Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a BetYahoo Finance·May 25, 2026
- Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQYahoo Finance·May 14, 2026
- Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to TradeYahoo Finance·May 7, 2026
- Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 5, 2026
- Insider Stock Buying Reaches US$2.07m On Nuvectis PharmaYahoo Finance·May 4, 2026
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research MeetingGlobeNewswire Inc.·Mar 31, 2026
- Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn SituationYahoo Finance·Mar 24, 2026
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business HighlightsYahoo Finance·Feb 11, 2026
- Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLCYahoo Finance·Dec 17, 2025
- Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insidersYahoo Finance·Dec 5, 2025
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLCYahoo Finance·Nov 25, 2025
- Director of Nuvectis Pharma Juan Sanchez Buys 20% More SharesYahoo Finance·Nov 8, 2025
- CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 4, 2025
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business HighlightsYahoo Finance·Nov 4, 2025
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 27, 2025
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsYahoo Finance·Oct 16, 2025
- Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth PlansYahoo Finance·Oct 15, 2025
All 22 articles loaded
Price Data
Open$16.03
Previous Close$16.53
Day High$18.24
Day Low$15.89
52 Week High$18.24
52 Week Low$5.55
52-Week Range
$5.55$18.24
$17.55
Fundamentals
Market Cap$471M
P/E Ratio—
EPS$-1.31
Dividend Yield—
Dividend / Share—
ROE-154.4%
Profit Margin—
Debt / Equity—
Trading
Volume281K
Avg Volume (10D)—
Shares Outstanding26.5M
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer. The company is headquartered in Fort Lee, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—